Nls Pharmaceutics Ltd (NLSP)

$1.30 -0.02 (-1.52%)
Market Cap 4.75M
Revenue (ttm) 0.00
Net Income (ttm) -1.98M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 319,100
Avg Vol 618,792
Day's Range N/A - N/A
Shares Out 3.60M
Stochastic %K 8%
Beta 0.14
Analysts Strong Buy
Price Target $4.00

Company Profile

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience for the treatment of narcolepsy; and N...

Industry: Biotechnology
Sector: Healthcare
Phone: 41 44 512 21 50
Fax: 41 44 512 21 51
Address:
The Circle 6, Zurich, Switzerland
Mister_Bungle
Mister_Bungle Oct. 24 at 8:40 PM
$NLSP manipulation hurts when you've invested so much in a company. Tanking this to 1 dollar from $3 is insane to me.
1 · Reply
yoni30
yoni30 Oct. 24 at 6:07 PM
$NLSP Why will there be a capital consolidation if the share price exceeds one dollar? I understand that the company needs to bring in shares for Kadimastem, so will there be an offering after the capital consolidation?
0 · Reply
madhawa
madhawa Oct. 24 at 4:52 PM
$NLSP Bought again with small lot.. seems like reversal is coming
0 · Reply
yoni30
yoni30 Oct. 24 at 2:57 PM
$NLSP The stock was stable around $2.8 Why did we need this stinking merger? It only caused trouble
0 · Reply
yoni30
yoni30 Oct. 24 at 1:48 PM
$NLSP Bottomless Stock And This Is Even After a Merger Bordering on the Criminal Side
0 · Reply
Carolinacatsfan
Carolinacatsfan Oct. 24 at 1:44 PM
$NLSP an absolute fucking dumpster fire this turned out to be, extremely disappointing and mind fucked as to how we can trade above 3-4 dollars just a couple months ago and now barely hanging on to a dollar post merger announcement. I have no choice but to wait for this shitshow to play out and hope to break even
0 · Reply
madhawa
madhawa Oct. 24 at 8:55 AM
$NLSP Crazy no buyers and some people are planning to sell @ 6 lol
1 · Reply
madhawa
madhawa Oct. 23 at 9:17 PM
$NLSP There are many shortage shares to short….
0 · Reply
yoni30
yoni30 Oct. 23 at 9:12 PM
$NLSP In your opinion, what will be the market value of NCEL? And what will be the share price?
1 · Reply
littlegretti
littlegretti Oct. 23 at 8:48 PM
$NLSP Just jumped on for a pre merger run (maybe run)
0 · Reply
Latest News on NLSP
NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025

Oct 23, 2025, 6:01 AM EDT - 2 days ago

NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025

NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting

Sep 30, 2025, 7:00 AM EDT - 25 days ago

NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting

Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger

Sep 10, 2025, 6:00 AM EDT - 6 weeks ago

Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger

NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients

Sep 4, 2025, 7:38 AM EDT - 7 weeks ago

NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients

NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy

Jul 17, 2025, 7:00 AM EDT - 3 months ago

NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy

NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing

Jun 30, 2025, 7:00 AM EDT - 4 months ago

NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing

NLS Pharmaceutics CEO Issues Letter to Shareholders

Jun 16, 2025, 7:00 AM EDT - 4 months ago

NLS Pharmaceutics CEO Issues Letter to Shareholders

NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting

May 21, 2025, 7:30 AM EDT - 5 months ago

NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting

NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models

Apr 15, 2025, 9:00 AM EDT - 6 months ago

NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement

Mar 31, 2025, 9:10 AM EDT - 7 months ago

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement

NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform

Feb 27, 2025, 7:00 AM EST - 8 months ago

NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

Feb 25, 2025, 9:05 AM EST - 8 months ago

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies

Feb 10, 2025, 7:30 AM EST - 9 months ago

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics

Jan 31, 2025, 7:30 AM EST - 9 months ago

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics

NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting

Jan 30, 2025, 7:30 AM EST - 9 months ago

NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting

NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence

Jan 28, 2025, 7:30 AM EST - 9 months ago

NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence

Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS

Jan 16, 2025, 9:32 AM EST - 10 months ago

Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS

NLS Pharmaceutics Ltd. and Kadimastem Ltd.

Jan 8, 2025, 7:42 AM EST - 10 months ago

NLS Pharmaceutics Ltd. and Kadimastem Ltd.

NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment

Dec 19, 2024, 7:30 AM EST - 11 months ago

NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment

NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the Market

Dec 4, 2024, 1:15 PM EST - 11 months ago

NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the Market

NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders

Dec 3, 2024, 7:40 AM EST - 11 months ago

NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders

NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders

Nov 18, 2024, 7:30 AM EST - 1 year ago

NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders

NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement

Nov 4, 2024, 7:00 AM EST - 1 year ago

NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement

NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements

Oct 28, 2024, 7:00 AM EDT - 1 year ago

NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements

NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence

Oct 21, 2024, 7:00 AM EDT - 1 year ago

NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence

NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules

Oct 15, 2024, 7:00 AM EDT - 1 year ago

NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules

NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split

Sep 25, 2024, 8:00 AM EDT - 1 year ago

NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split

Crude Oil Moves Lower; NLS Pharmaceutics Shares Jump

Jul 29, 2024, 12:03 PM EDT - 1 year ago

Crude Oil Moves Lower; NLS Pharmaceutics Shares Jump

NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge

Jul 29, 2024, 7:00 AM EDT - 1 year ago

NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge

NLS Pharmaceutics Announces Registered Direct Offering

Jun 28, 2024, 9:00 AM EDT - 1 year ago

NLS Pharmaceutics Announces Registered Direct Offering

NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease Treatments

Jun 27, 2024, 8:00 AM EDT - 1 year ago

NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease Treatments

Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements

Jun 25, 2024, 8:30 AM EDT - 1 year ago

Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements

NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)

Jun 11, 2024, 8:30 AM EDT - 1 year ago

NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)

NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing

Apr 19, 2024, 5:00 PM EDT - 1 year ago

NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing

NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering

Mar 22, 2024, 4:30 PM EDT - 1 year ago

NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering

NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering

Mar 20, 2024, 1:40 PM EDT - 1 year ago

NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering

NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform

Mar 20, 2024, 7:30 AM EDT - 1 year ago

NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform

NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event

Mar 14, 2024, 8:00 AM EDT - 1 year ago

NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event

Nasdaq Accepts NLS Pharmaceutics' Plan to Regain Listing Compliance

Mar 11, 2024, 7:00 AM EDT - 1 year ago

Nasdaq Accepts NLS Pharmaceutics' Plan to Regain Listing Compliance

NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq

Feb 23, 2024, 7:30 AM EST - 1 year ago

NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq

Notice of Deficiency with Nasdaq Continued Listing Requirements

Jan 12, 2024, 4:30 PM EST - 1 year ago

Notice of Deficiency with Nasdaq Continued Listing Requirements

NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.

Dec 1, 2023, 7:30 AM EST - 2 years ago

NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.

NLS Pharmaceutics Announces Election of Additional Board Members

Nov 28, 2023, 7:30 AM EST - 2 years ago

NLS Pharmaceutics Announces Election of Additional Board Members

NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomnia

Nov 27, 2023, 8:30 AM EST - 2 years ago

NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomnia

NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge Loan

Nov 16, 2023, 8:00 AM EST - 2 years ago

NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge Loan

NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification

Oct 25, 2023, 4:30 PM EDT - 2 years ago

NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification

NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions

Oct 19, 2023, 5:00 PM EDT - 2 years ago

NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions

NLS Pharmaceutics Announces Company Update on Strategic Partnerships

Oct 12, 2023, 9:40 AM EDT - 2 years ago

NLS Pharmaceutics Announces Company Update on Strategic Partnerships

NLS Pharmaceutics shares rise as narcolepsy treatment moves to phase 3 studies

Jul 3, 2023, 8:53 AM EDT - 2 years ago

NLS Pharmaceutics shares rise as narcolepsy treatment moves to phase 3 studies

NLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol

Jul 3, 2023, 7:00 AM EDT - 2 years ago

NLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol

Mister_Bungle
Mister_Bungle Oct. 24 at 8:40 PM
$NLSP manipulation hurts when you've invested so much in a company. Tanking this to 1 dollar from $3 is insane to me.
1 · Reply
yoni30
yoni30 Oct. 24 at 6:07 PM
$NLSP Why will there be a capital consolidation if the share price exceeds one dollar? I understand that the company needs to bring in shares for Kadimastem, so will there be an offering after the capital consolidation?
0 · Reply
madhawa
madhawa Oct. 24 at 4:52 PM
$NLSP Bought again with small lot.. seems like reversal is coming
0 · Reply
yoni30
yoni30 Oct. 24 at 2:57 PM
$NLSP The stock was stable around $2.8 Why did we need this stinking merger? It only caused trouble
0 · Reply
yoni30
yoni30 Oct. 24 at 1:48 PM
$NLSP Bottomless Stock And This Is Even After a Merger Bordering on the Criminal Side
0 · Reply
Carolinacatsfan
Carolinacatsfan Oct. 24 at 1:44 PM
$NLSP an absolute fucking dumpster fire this turned out to be, extremely disappointing and mind fucked as to how we can trade above 3-4 dollars just a couple months ago and now barely hanging on to a dollar post merger announcement. I have no choice but to wait for this shitshow to play out and hope to break even
0 · Reply
madhawa
madhawa Oct. 24 at 8:55 AM
$NLSP Crazy no buyers and some people are planning to sell @ 6 lol
1 · Reply
madhawa
madhawa Oct. 23 at 9:17 PM
$NLSP There are many shortage shares to short….
0 · Reply
yoni30
yoni30 Oct. 23 at 9:12 PM
$NLSP In your opinion, what will be the market value of NCEL? And what will be the share price?
1 · Reply
littlegretti
littlegretti Oct. 23 at 8:48 PM
$NLSP Just jumped on for a pre merger run (maybe run)
0 · Reply
Carolinacatsfan
Carolinacatsfan Oct. 23 at 8:18 PM
$NLSP the CEO deserves to be fired before he even begins
1 · Reply
yoni30
yoni30 Oct. 23 at 8:15 PM
$NLSP Until NCEL starts trading, we will probably continue to decline. What is happening here is a disgrace. It is upside down and goes against all common sense.
1 · Reply
GluttonBoy
GluttonBoy Oct. 23 at 7:36 PM
GTIM will be the next $BYND Unfound profitable gem. It’s still early. This will go parabolic very soon. $SCNX $NLSP $AREB $BENF watching these too
0 · Reply
madhawa
madhawa Oct. 23 at 7:34 PM
$NLSP lol 40% Drop from today’s high… going in to sub $1
0 · Reply
MansasAlgo
MansasAlgo Oct. 23 at 7:06 PM
$NLSP How will the market value $NCEL at the start of trading? NLS shareholders also approved stock reverse split?
0 · Reply
MansasAlgo
MansasAlgo Oct. 23 at 5:45 PM
$NLSP ouch
0 · Reply
yoni30
yoni30 Oct. 23 at 5:39 PM
$NLSP Reading the stock symbol to pieces Simply crazy Disgusting A whole month of it falling
1 · Reply
madhawa
madhawa Oct. 23 at 5:36 PM
$NLSP No Trade is the best trade
0 · Reply
madhawa
madhawa Oct. 23 at 5:07 PM
$NLSP Tomorrow we might see another 10% drop :)
1 · Reply
Diverter
Diverter Oct. 23 at 4:24 PM
$NLSP no more good news 🗞️ we have enough
0 · Reply
yoni30
yoni30 Oct. 23 at 3:44 PM
$NLSP What's happening with the stock is crazy What's going on there?
0 · Reply
madhawa
madhawa Oct. 23 at 3:18 PM
$NLSP does NLSP get any preffered shares with the merger.. ?
0 · Reply